SIL 1002
Alternative Names: SIL-1002; SL-1002Latest Information Update: 04 Nov 2024
Price :
$50 *
At a glance
- Originator Saol Therapeutics
- Class Analgesics; Antispastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Muscle spasticity; Musculoskeletal pain
Most Recent Events
- 30 Oct 2024 Saol Therapeutics plans to meet with the US FDA in the first half of 2025 to determine the next steps for SL 1002
- 30 Oct 2024 Efficacy and adverse events data from a phase II clinical trials in Muscle spasticity released by Saol Therapeutics
- 19 Sep 2023 Saol Therapeutics plans a phase III trial for Limb Spasticity and Knee pain associated with Osteoarthritis